Skip to main content

Table 2 Clinical and parasitological failure by day 14 and day 28

From: Adding artesunate to sulphadoxine-pyrimethamine greatly improves the treatment efficacy in children with uncomplicated falciparum malaria on the coast of Benin, West Africa

 

CQ

SP

SP – AS

DAY 14, n

71

70

77

ACPR

32 (45.1)

46 (65.7)

76 (98.7)

ETF, n (%)

18 (25.4)

16 (22.9)

0 (0.0)

LCF, n (%)

6 (8.5)

2 (2.9)

0 (0.0)

LPF, n (%)

15 (21.1)

6 (8.6)

1 (1.3)

TOTAL FAILURES

   

   Per protocol, n (%)

39 (54.9)

24 (34.3)

1 (1.3)

   Intention to Treat, n (%)

47/79 (59.5)

31/77 (40.3)

5/81 (6.2)

DAY 28 (PCR uncorrected), n

71

68

76

ACPR

18 (25.4)

37 (54.4)

68 (89.5)

ETF, n (%)

18 (25.4)

16 (23.5)

0 (0.0)

LCF, n (%)

8 (11.3)

4 (5.9)

1 (1.3)

LPF, n (%)

27 (38.0)

11 (16.2)

7 (9.2)

TOTAL FAILURES

   

   Per protocol, n (%)

53 (74.6)

31 (45.6)

8 (10.5)

   Intention to Treat, n (%)

61 (77.2)

40 (51.9)

13 (16.0)

DAY 28 (PCR corrected)

   

ACPR

20 (28.2)

38 (55.9)

72 (94.7)

ETF, n (%)

18 (25.4)

16 (23.5)

0 (0.0)

LCF, n (%)

8 (11.3)

4 (5.9)

1 (1.3)

LPF, n (%)

25 (35.2)

10 (14.7)

3 (3.9)

TOTAL FAILURES

   

   New infections, n (%)

2 (14.3)

1 (14.3)

4 (57.1)

   Per protocol, n (%)

51 (71.8)

30 (44.1)

4 (5.3)

   Intention to Treat, n (%)

59 (74.7)

39 (50.6)

9 (11.1)

   Kaplan Meier survival analysis (%)

71.8

42.0

5.3